Short-term efficacy of oral low-dose Tegafur chemotherapy after transarterial chemoembolization in primary hepatic carcinoma.
To observe the short-term efficacy of oral low-dose Tegafur chemotherapy after transarterial chemoembolization (TACE) in primary hepatic carcinoma (PHC). 120 PHC patients undergoing TACE treatment for the first were randomly divided into the Tegafur group and the TACE group. Patients in TACE group received TACE only, whereas those in the Tegafur group received TACE and postoperative oral low-dose Tegafur chemotherapy. All patients were followed up for 4 to 20 months. Clinical efficacy, liver function changes, progression-free survival (PFS), and adverse reactions were compared between the two groups. The disease control rate (DCR) and clinical benefit rate (CBR) of the Tegafur group were significantly higher than those of TACE group (p<0.05). Moreover, higher PFS was found in the Tegafur group than that of the TACE group after 18 months of follow-up (p<0.05). Before treatment, serum levels of ALT, AST, TBIL and DBIL in the two groups were not statistically significant (p>0.05). After treatment, the above-mentioned indicators were remarkably increased in both groups. In particular, the indicators were lower in the Tegafur group than those of the TACE group (p<0.05). TACE combined with low-dose Tegafur for treating PHC can slow down the tumor progression and prolong the PFS. This approach is safe and effective.